Flex Pharma,Inc. (NASDAQ:FLKS) Files An 8-K Results of Operations and Financial ConditionItem 2.02 Results of Operations and Financial Condition.
On November 6, 2017, Flex Pharma,Inc. (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2017. A copy of the press release is attached hereto as Exhibit99.1 and incorporated herein by reference.
The information in this Item 2.02 and Exhibit99.1 hereto is being furnished and shall not be deemed “filed” for the purposes of Section18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.
Item 8.01 Other Events.
On November 6, 2017, the Company issued a press release relating to the results from its clinical trial of amyotrophic lateral sclerosis (ALS) patients with frequent muscle cramps. The Company will host a conference call and live webcast with a slide presentation on Monday, November 6, at 8:45 a.m. EDT. A copy of this press release and slide presentation are filed herewith as Exhibits 99.2 and 99.3, respectively, and the information contained therein is incorporated by reference into this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Flex Pharma, Inc. ExhibitEX-99.1 2 flks201709308-kpr.htm EXHIBIT 99.1 Exhibit Flex Pharma Reports Third Quarter 2017 Financial Results– Recent Positive Topline Data Reported from Exploratory Phase 2 Trial of FLX-787 in ALS —- Two US Phase 2b Trials in ALS and CMT Initiated under IND; Data Readouts in 2018 —- Development Efforts Expanding into Dysphasia –Conference Call Scheduled Today at 8:45 a.m. ETNovember 6,…To view the full exhibit click here
About Flex Pharma,Inc. (NASDAQ:FLKS)
Flex Pharma, Inc. is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company’s product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms. The Company operates through developing and commercializing products for nocturnal leg cramps, muscle cramps, spasms and spasticity associated with severe neuromuscular conditions, and exercise-associated muscle cramps segment. The Company’s lead drug product candidate is FLX-787, which is in the Phase II clinical trial stage. It is developing a consumer brand and products specifically formulated to treat athletes suffering from EAMCs.
